ASCO: Keytruda Inches Uncertainly Towards Tecentriq In Triple-Negative Breast Cancer

KEYNOTE-355 Mixed On PFS; Still Waiting On OS

Merck & Co is gradually catching up with Roche in PD-1/L1 first-line triple-negative breast cancer treatment, but its presentation at ASCO on Keynote-355 includes mixed PFS results. Overall survival data will be key to Keytruda’s competitiveness.

New data to be presented by Merck & Co. Inc. at the upcoming American Society of Clinical Oncology virtual meeting represent a step forward in its bid to challenge Roche’s stronghold in immunotherapy for triple-negative breast cancer. However, Roche need not start quaking in its boots just yet.

Merck is set to present updated results on its PD-1 inhibitor Keytruda (pembrolizumab) in first-line treatment of triple-negative breast cancer...